Clinical trials: asthma
Asthma
A Blinded, Dose Ascending Study to Assess the Pharmacokinetics, Safety and Tollerability of Repeat Inhaled Doses of Nebulised GW870086X in Healthy Adult Male Volunteers.
This study is a randomised, double-blind, placebo-controlled, dose ascending, 3-way crossover study in healthy adult male volunteers.
- Trial name
- SIG (NCT01160003)
- Testing
- GW870086X
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Aspergillosis
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945
PC945 is a new medicine being developed for treatment of fungal lung diseases. The main purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of PC945
- Trial name
- NCT02715570
- Testing
- PC945 - single doses, PC945 - repeat doses
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Pulmocide Ltd
Asthma
Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response
We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist (LABA)/ inhaled corticosteroid (ICS) combination product on protection from…
- Trial name
- NCT01128569
- Testing
- Fluticasone Furoate, FF/Vilanterol (VI; GW642444M)
- Where
- 4 sites in Germany, New Zealand and 1 more
- Volunteers
- 52 people
- Sponsor
- GlaxoSmithKline
Asthma
A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma
Primary Objective: To assess the effect of dupilumab on sleep Secondary Objectives: To evaluate the effect of dupilumab on additional participant reported sleep outcomes To evaluate the effect of dupilumab on objective sleep…
- Trial name
- MORPHEO (NCT04502862)
- Testing
- SAR231893
- Where
- 55 sites in United States, Argentina and 9 more
- Volunteers
- 202 people
- Sponsor
- Sanofi
Asthma
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5
The purpose of this study is to compare Symbicort with budesonide alone and with formoterol alone in the treatment of asthma in adolescents and adults
- Trial name
- NCT00652002
- Testing
- budesonide/formoterol, budesonide, formoterol
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Asthma
A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma
To demonstrate that CHF 1535 via NEXT DPI (beclomethasone dipropionate + formoterol fumarate 100 + 6 μg), 1 inhalation or 2 inhalations twice daily, for 12 weeks is non-inferior to the corresponding dose of CHF 1535 via HFA-134a…
- Trial name
- NCT00862394
- Testing
- BDP/Formoterol Next DPI, Foster
- Where
- Germany
- Volunteers
- 783 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Study to Evaluate the Pharmacokinetic Profile of Salbutamol Delivered by Unit Dose Dry Powder Inhaler (UD-DPI) Compared to the Diskus and Metered Dose Inhaler (MDI) in Healthy Volunteers.
This is an open-label, two part, six period- cross over, randomised, single dose, single centre study in healthy subjects. This is the first clinical study for the UD-DPI. This study is divided into two parts.
- Trial name
- NCT01984086
- Testing
- Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend), Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend), Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend)
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma, Allergy
Efficacy of Air Cleaners in Asthmatics Allergic to Cat in ALYATEC Environmental Exposure Chamber
The aim of this study is to determine the efficacy of Rowenta® "Intense Pure Air XL" air cleaner on the early and late bronchial response, in cat-allergic asthmatic patients during an allergen exposure in ALYATEC environmental…
- Trial name
- NCT03928561
- Testing
- Active intense Pure Air XL air cleaner
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Alyatec
Asthma
Japanese Phase 1 Study of Mepolizumab
SB-240563 is a fully humanized monoclonal antibody which is specific for human interleukin-5 (IL-5) and has been under development for severe refractory asthma. This study is the first study in Japanese subjects.
- Trial name
- NCT01471327
- Testing
- SB-240563
- Where
- Australia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma, Bronchial, Lung Diseases, Obstructive
A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects
This study (A7881006) is the first multiple dose study in moderate asthmatic subjects and aims to determine the safety and efficacy of PF-00610355 when subjects take PF-00610355 on a daily basis for 4 weeks in subjects maintained…
- Conditions
- Asthma, Bronchial, Lung Diseases, Obstructive, Respiratory Tract Diseases, Bronchial Diseases
- Trial name
- A7881006 (NCT00830427)
- Testing
- PF-00610355, PF - 00610355
- Sponsor
- Pfizer
Asthma (Diagnosis)
ADO-5030 in Bronchoconstriction Challenge, Phase 1b
This is a Phase 1 study to learn about the safety and pharmacokinetics of the study drug in patients with asthma and whether the study drug has effect during a respiratory challenge.
- Trial name
- NCT07281274
- Testing
- ADO-5030
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Adovate
Asthma
Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose - ADERE PROJECT
Prospective, parallel-group, randomized study to evaluate the compliance to the treatment of children aged between 6 and 14 years old with persistent moderate or severe asthma, receiving the association Fluticasone 250 mcg/dose…
- Trial name
- ADERE (Ped) (NCT01476059)
- Testing
- Telephone follow-up, No telephone follow-up
- Volunteers
- 472 people
- Sponsor
- GlaxoSmithKline
Asthma
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
- Trial name
- NCT00603382
- Testing
- GW685698X
- Where
- 149 sites in United States, Bulgaria and 12 more
- Volunteers
- 599 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
The main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and…
- Trial name
- AIRITY (NCT07556159)
- Testing
- Procedure: Investigational Procedures
- Where
- 83 sites in United States, Canada and 4 more
- Volunteers
- 2,500 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease (COPD), Asthma
A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants
AZD7594 is a non steroidal, potent and selective modulator of the glucocorticoid receptor (GR) under development for once daily inhaled treatment of chronic obstructive pulmonary disease (COPD) and asthma.
- Trial name
- NCT02967159
- Testing
- Abediterol, AZD7594, AZD7594/abediterol
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids
To investigate the effectiveness and safety of BI 671800 given in the morning (AM), evening (PM) or twice daily (b.i.d.) compared too placebo as add on therapy to inhaled corticosteroid in symptomatic asthma patients.
- Trial name
- NCT01090024
- Testing
- BI 671800
- Where
- 14 sites in United States
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Asthma
Improved Quality of the Treatment and Increased Compliance in Asthmatics Through the Dialog Tool Soren - Between Patient and Caregiver
The purpose of the study is to assess if a dialog tool can improve compliance and asthma control in patients with asthma.
- Trial name
- NCT00272727
- Testing
- Dialog tool for caregivers
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Asthma
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled…
- Trial name
- NCT07301255
- Testing
- ENV-294
- Where
- 20 sites in United States
- Volunteers
- 50 people
- Sponsor
- Enveda Therapeutics
Asthma
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging
This study will assess the effects of benralizumab on airway dynamics in severe eosinophilic asthma in terms of quantitative computed tomography (CT)-derived measurements of pulmonary structure and function using the Functional…
- Trial name
- BURAN (NCT05552508)
- Testing
- Benralizumab
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Asthma
Effect of RNS60 on the Late Phase Asthmatic Response to Allergen Challenge
The study will investigate the effect of treatment with RNS60 for 21 days. Subjects' FEV1 will be measured after an inhaled allergen challenge at baseline and again after 21 days of treatment.
- Trial name
- NCT02422121
- Testing
- RNS60
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Revalesio Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.